Lopinavir / Ritonavir — Competitive Intelligence Brief

Lopinavir / Ritonavir (Lopinavir / Ritonavir) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HIV protease inhibitor. Area: Infectious Disease.

marketed HIV protease inhibitor HIV protease Infectious Disease Small molecule

Target snapshot

Lopinavir / Ritonavir (Lopinavir / Ritonavir) — Baqiyatallah Medical Sciences University. Lopinavir and ritonavir are protease inhibitors that block HIV protease, preventing the cleavage of viral polyproteins and inhibiting viral replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lopinavir / Ritonavir TARGET	Lopinavir / Ritonavir	Baqiyatallah Medical Sciences University	marketed	HIV protease inhibitor	HIV protease
Switch ritonavir-boosted PI	Switch ritonavir-boosted PI	Juan A. Arnaiz	marketed	Protease inhibitor (boosted)	HIV protease
TMC114/ritonavir	TMC114/ritonavir	Janssen-Cilag Ltd.	marketed	HIV protease inhibitor	HIV protease
Ritonavir (heat-stable)	Ritonavir (heat-stable)	Bristol-Myers Squibb	marketed	HIV protease inhibitor	HIV protease
Ritonavir boosted Atazanavir + 2 NRTIs	Ritonavir boosted Atazanavir + 2 NRTIs	Fundacion SEIMC-GESIDA	marketed	Protease inhibitor combination antiretroviral therapy	HIV protease, HIV reverse transcriptase
Antiretroviral therapy	Antiretroviral therapy	ANRS, Emerging Infectious Diseases	marketed	Combination antiretroviral therapy (multiple classes: nucleoside/nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase strand transfer inhibitors, entry inhibitors)	HIV reverse transcriptase, HIV integrase, HIV protease, HIV envelope glycoproteins (gp120/gp41), CCR5 co-receptor
Tenofovir + emtricitabine + lopinavir/ritonavir	Tenofovir + emtricitabine + lopinavir/ritonavir	Juan A. Arnaiz	marketed	Antiretroviral combination (NRTI + protease inhibitor)	HIV reverse transcriptase, HIV protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HIV protease inhibitor class)

1. Bristol-Myers Squibb · 5 drugs in this class
2. ViiV Healthcare · 3 drugs in this class
3. GlaxoSmithKline · 2 drugs in this class
4. Drugs for Neglected Diseases · 2 drugs in this class
5. Germans Trias i Pujol Hospital · 2 drugs in this class
6. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
7. DualityBio Inc. · 1 drug in this class
8. French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
9. Far East Bio-Tec Co., Ltd · 1 drug in this class
10. Community Research Initiative of New England · 1 drug in this class